Bruker Corporation (Nasdaq: BRKR) announces that it has entered into a definitive share purchase agreement with TecFin S.à r.l., a controlled affiliate of PAI Partners, a pre-eminent private equity firm, to acquire ELITechGroup, for €870 million in cash, excluding the carved out ELITech clinical chemistry business. ELITechGroup, with over 500 employees and over 40 active patents, develops and commercializes innovative, proprietary molecular diagnostic (MDx) systems and assays, as well as niche biomedical systems and microbiology products. Its molecular diagnostic business accounts for the majority of the to-be-acquired revenues and provides the unique sample-to-answer (S2A) instruments InGenius® and BeGenius® in the mid-to-high throughput MDx category.
Read the full article: Bruker Announces Share Purchase Agreement to Acquire Molecular Diagnostics Innovator ELITechGroup //
Source: https://www.businesswire.com/news/home/20240228291399/en/Bruker-Announces-Share-Purchase-Agreement-to-Acquire-Molecular-Diagnostics-Innovator-ELITechGroup